168 related articles for article (PubMed ID: 24817629)
1. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.
Son JY; Park SY; Kim SJ; Lee SJ; Park SA; Kim MJ; Kim SW; Kim DK; Nam JS; Sheen YY
Mol Cancer Ther; 2014 Jul; 13(7):1704-16. PubMed ID: 24817629
[TBL] [Abstract][Full Text] [Related]
2. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
[TBL] [Abstract][Full Text] [Related]
3. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
4. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
[TBL] [Abstract][Full Text] [Related]
5. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
[TBL] [Abstract][Full Text] [Related]
7. An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Rausch MP; Hahn T; Ramanathapuram L; Bradley-Dunlop D; Mahadevan D; Mercado-Pimentel ME; Runyan RB; Besselsen DG; Zhang X; Cheung HK; Lee WC; Ling LE; Akporiaye ET
Anticancer Res; 2009 Jun; 29(6):2099-109. PubMed ID: 19528470
[TBL] [Abstract][Full Text] [Related]
8. EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling.
Park SA; Kim MJ; Park SY; Kim JS; Lee SJ; Woo HA; Kim DK; Nam JS; Sheen YY
Cell Mol Life Sci; 2015 May; 72(10):2023-39. PubMed ID: 25487606
[TBL] [Abstract][Full Text] [Related]
9. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
[TBL] [Abstract][Full Text] [Related]
10. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.
Bouquet F; Pal A; Pilones KA; Demaria S; Hann B; Akhurst RJ; Babb JS; Lonning SM; DeWyngaert JK; Formenti SC; Barcellos-Hoff MH
Clin Cancer Res; 2011 Nov; 17(21):6754-65. PubMed ID: 22028490
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.
Bandyopadhyay A; Agyin JK; Wang L; Tang Y; Lei X; Story BM; Cornell JE; Pollock BH; Mundy GR; Sun LZ
Cancer Res; 2006 Jul; 66(13):6714-21. PubMed ID: 16818646
[TBL] [Abstract][Full Text] [Related]
12. TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition.
Kim MJ; Park SA; Kim CH; Park SY; Kim JS; Kim DK; Nam JS; Sheen YY
Cell Physiol Biochem; 2016; 38(2):571-88. PubMed ID: 26845171
[TBL] [Abstract][Full Text] [Related]
13. EW-7197, an activin-like kinase 5 inhibitor, suppresses granulation tissue after stent placement in rat esophagus.
Jun EJ; Park JH; Tsauo J; Yang SG; Kim DK; Kim KY; Kim MT; Yoon SH; Lim YJ; Song HY
Gastrointest Endosc; 2017 Jul; 86(1):219-228. PubMed ID: 28137596
[TBL] [Abstract][Full Text] [Related]
14. Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer.
Choi J; Park J; Cho I; Sheen Y
Radiol Oncol; 2022 Apr; 56(2):185-197. PubMed ID: 35390248
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Krishnaiah M; Jin CH; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.
Bandyopadhyay A; Wang L; Agyin J; Tang Y; Lin S; Yeh IT; De K; Sun LZ
PLoS One; 2010 Apr; 5(4):e10365. PubMed ID: 20442777
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase.
Buijs JT; Matula KM; Cheung H; Kruithof-de Julio M; van der Mark MH; Snoeks TJ; Cohen R; Corver WE; Mohammad KS; Jonkers J; Guise TA; van der Pluijm G
J Pathol; 2015 Apr; 235(5):745-59. PubMed ID: 25421310
[TBL] [Abstract][Full Text] [Related]
18. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor
Spender LC; Ferguson GJ; Hughes GD; Davies BR; Goldberg FW; Herrera B; Taylor RG; Strathearn LS; Sansom OJ; Barry ST; Inman GJ
Mol Pharmacol; 2019 Feb; 95(2):222-234. PubMed ID: 30459156
[TBL] [Abstract][Full Text] [Related]
20. Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.
Naka K; Ishihara K; Jomen Y; Jin CH; Kim DH; Gu YK; Jeong ES; Li S; Krause DS; Kim DW; Bae E; Takihara Y; Hirao A; Oshima H; Oshima M; Ooshima A; Sheen YY; Kim SJ; Kim DK
Cancer Sci; 2016 Feb; 107(2):140-8. PubMed ID: 26583567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
